Comparison of bariatric surgical procedures for diabetes remission: Efficacy and mechanisms

Diabetes Spectrum

Volumn 25, Issue 4, 2012, Pages 200-210

  Vetter, Marion L ^a,b,c   Ritter, Scott ^a,c   Wadden, Thomas A ^a,c,d   Sarwer, David B ^a,c,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Division of Endocrinology   (United States)

^c Ctr for Eating and Weight Disorders   (United States)

^d Department of Psychiatry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; PEPTIDE YY;

ADJUSTABLE GASTRIC BAND; BARIATRIC SURGERY; BILIOPANCREATIC DIVERSION WITH A DUODENAL SWITCH; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN SENSITIVITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RELAPSE; REMISSION; REVIEW; ROUX Y ANASTOMOSIS; STOMACH EMPTYING; SURGICAL TECHNIQUE; VERTICAL SLEEVE GASTRECTOMY; WEIGHT REDUCTION;

EID: 84871214920     PISSN: 10409165     EISSN: 19447353     Source Type: Journal    
DOI: 10.2337/diaspect.25.4.200     Document Type: Review

References (108)

1. Flegal KM, Carroll MD, Kit BK, Ogden CL: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307:491-497, 2012
2. Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM: Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med 30:371-377, 2006
3. Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-Arvizu R: Increasing BMI and waist circumference and prevalence of obesity among adults with type 2 diabetes: the National Health and Nutrition Examination Surveys. J Diabetes Complications 24:368-374, 2010
4. Centers for Disease Control and Prevention: National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, Ga., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
5. Colquitt JL, Picot J, Loveman E, Clegg AJ: Surgery for obesity. Cochrane Database Syst Rev 2:CD003641, 2009
6. Taylor K: Metabolic and bariatric surgery fact sheet [article online]. Available from www.asmbs.org/asmbs-press-kit. Accessed 3 April 2012
7. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM, Dohm L: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339-350, 1995
8. Vetter ML, Cardillo S, Rickels MR, Iqbal N: Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 150:94-103, 2009
9. NIDDK Weight Information Network: Bariatric surgery for severe obesity [article online]. Available from www.win.niddk.nih.gov/publications/gastric.htm. Accessed 3 April 2012
10. Cummings DE, Overduin J, Shannon MH, Foster-Schubert KE: Hormonal mechanisms of weight loss and diabetes resolution after bariatric surgery. Surg Obes Rel Dis 1:358-368, 2005
11. Perugini RA, Malkani S: Remission of type diabetes following bariatric surgery: review of mechanisms and concept of 'reversibility.' Curr Opin Endocrinol Diabetes Obes 18:119-128, 2011
12. Buchwald H, Oien DM: Metabolic/bariatric surgery worldwide 2008. Obes Surg 19:1605-1611, 2008
13. de Jong JR, van Ramshorst B, Gooszen HG, Smout AJ, Tiel-Van Buul MM: Weight loss after laparoscopic adjustable gastric banding is not caused by altered gastric emptying. Obes Surg 19:287-292, 2009
14. Data Laparoscopy Research Team (iData Research): US market for laparoscopic devices. Vancouver, B.C., iData Research Inc., 2009
15. Braghetto I, Davanzo C, Korn O, Csendes A, Valladares H, Herrera E, Gonzalez P, Papapietro K: Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg 19:1515-1521, 2009
16. Melissas J, Koukouraki S, Askoxylakis J, Stathaki M, Daskalakis M, Perisinakis K, Karkavitsas N: Sleeve gastrectomy: a restrictive procedure? Obes Surg 17:57-62, 2007
17. Rubino F: Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care 9:497-507, 2006
18. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724-1737, 2004
19. Ferchak CV, Meneghini LF: Obesity, bariatric surgery, and type 2 diabetes: a systematic review. Diabetes Metab Res Rev 20:438-445, 2004
20. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG: Metaanalysis: surgical treatment of obesity. Ann Intern Med 142:547-559, 2005
21. Shah M, Simha V, Garg A: Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab 91:4223-4231, 2006
22. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 122:248-256, 2009
23. Angrisani L, Lorenzo M, Borrelli V: Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Dis 3:127-132, 2007
24. Nguyen NT, Slone JA, Nguyen XM, Hartman JS, Hoyt DB: A prospective randomized trial of laparoscopic gastric bypass versus laparoscopic adjustable gastric banding for the treatment of morbid obesity: outcomes, quality of life, and costs. Ann Surg 250:631-641, 2009
25. Himpens J, Dapri G, Cadière GB: A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg 16:1450-1456, 2006
26. Peterli R, Wölnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe J, von Flüe M, Beglinger C: Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 250:234-241, 2009
27. Lee WJ, Ser KH, Chong K, Lee YC, Chen SC, Tsou JJ, Chen JC, Chen CM: Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change in insulin secretion. Surgery 147:664-669, 2010
28. 2. Obes Surg 21:1650-1656, 2011
29. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693, 2004
30. Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS: How do we define cure of diabetes? Diabetes Care 32:2133-2135, 2009
31. Dixon JB, Pories WJ, O'Brien PE, Schauer PR, Zimmet P: Surgery as an effective early intervention for diabesity: why the reluctance? Diabetes Care 28:472-474, 2005
32. Pournaras DJ, Aasheim ET, Søvik TT, Andrews R, Mahon D, Welbourn R, Olbers T, le Roux CW: Effect of definition of type II diabetes remission in the evaluation for bariatric surgery for metabolic disorders. Br J Surg 99:100-103, 2012
33. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316-323, 2008
34. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL: Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366:1567-1576, 2012
35. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F: Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577-1585, 2012
36. Wadden TA, Volger S, Sarwer DB, Vetter ML, Tsai AG, Berkowitz RI, Kumanyika S, Schmitz KH, Diewald LK, Barg R, Chittams J, Moore RH: A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 365:1969-1979, 2011
37. Appel LJ, Clark JM, Yeh HC, Wang NY, Coughlin JW, Daumit G, Miller ER 3rd, Dalcin A, Jerome GJ, Geller S, Noronha G, Pozefsky T, Charleston J, Reynolds JB, Durkin N, Rubin RR, Louis TA, Brancati FL: Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 365:1959-1968, 2011
38. Bennett GG, Warner ET, Glasgow RE, Askew S, Goldman J, Ritzwoller DP, Emmons KM, Rosner BA, Colditz GA: Obesity treatment for socioeconomically disadvantaged patients in primary care practice. Arch Intern Med 172:565-574, 2012
39. Torquati A, Lutfi R, Abumrad N, Richards WO: Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 9:1112-1116, 2005
40. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D: Effect of lapaoroscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238:467-484, 2003
41. Sugerman HJ, Wolfe LG, Sica DA, Clore JN: Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 237:751-756, 2003
42. Sarwer DB, Wadden TA, Moore RH, Baker AW, Gibbons LM, Raper SE, Williams NN: Preoperative eating behavior, postoperative dietary adherence, and weight loss after gastric bypass surgery. Surg Obes Relat Dis 4:640-646, 2008
43. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 77:1287-1293, 1993
44. Isbell JM, Tamboli RA, Hansen EN, Saliba J, Dunn JP, Phillips SE, Marks-Shulman PA, Abumrad NN: The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass. Diabetes Care 33:1438-1442, 2010
45. Ozer K, Abdelnour S, Alva AS: The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric by-pass surgery: comment on Isbell et al. Diabetes Care 33:e176, 2010
46. Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439, 2007
47. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A: The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric empyting, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781-792, 2001
48. Legakis IN, Tzioras C, Phenekos C: Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care 26:252, 2003
49. Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B: Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709-1716, 2007
50. Laferrère B, Tran H, Egger JR, Teixeira J, McGinty J, Yap K, Bawa B, Olivan B: The increase in GLP-1 levels and incretin effect after Roux-en-Y gastric bypass surgery (RYGBP) persists up to 1 year in patients with type 2 diabetes mellitus (T2DM) [Abstract]. Obesity 15:7, 2007
51. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ: Exaggerated glucagon-like peptide 1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3:597-601, 2007
52. Laferrère B, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, Kovack B, Bawa B, Koshy N, Lee H, Yapp K, Olivan B: Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 93:2479-2485, 2008
53. Mingrone G, Nolfe G, Gissey GC, Iaconelli A, Leccesi L, Guidone C, Nanni G, Holst JJ: Circadian rhythms of GIP and GLP-1 in glucose tolerant and in type 2 diabetics after biliopancreatic diversion. Diabetologia 52:873-881, 2009
54. Salinary S, Bertuzzi A, Asnaghi S, Guidone C, Manco M, Mingrone G: First-phase insulin secretion and restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 32:375-380, 2009
55. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK: Weight loss, appetite suppression, and changes and in fasting and postprandial ghrelin and peptide-YY after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 247:401-407, 2008
56. Raufman JP, Singh L, Eng J: Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas: description of exendin-3(9-39) amide, a specific exendin receptor antagonist. J Biol Chem 266:2897-2902, 1991
57. Eng J, Kleiman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 267:7402-7405, 1992
58. Wang Z, Wang RM, Owji AA, Smith DM, Ghatel MA, Bloom SR: Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95:417-421, 1995
59. D'Alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW: Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138, 1996
60. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M: Exendin (9-39) amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 101:1421-1430, 1998
61. Kindel TL, Yoder SM, Seeley RJ, D'Alessio DA, Tso P: Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptormediated mechanism. J Gastrointest Surg 13:1762-1772, 2009
62. Salehi M, Prigeon RL, D'Alessio DA: Gastric bypass surgery enhances glucagon-like peptide-1 stimulated postprandial insulin secretion in humans. Diabetes 60:2308-2314, 2011
63. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B: Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 107:1-13, 2002
64. Krarup T: Immunoreactive gastric inhibitory polypeptide. Endocr Rev 9:122-134, 1988
65. Ross SA, Brown JC, Dupré J: Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26:525-529, 1977
66. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ: Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678-687, 2008
67. Vilsbøll T, Krarup T, Madsbad S, Holst JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119, 2002
68. Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ: The pathophysiology of diabetes involves a defective amplification of late phase insulin response to glucose by glucose-dependent insulkinotropic polypeptide- regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897-4903, 2003
69. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL: Hormonal changes after Roux-en-Y gastric bypass for morbid obesity and the control of type 2 diabetes mellitus. Am Surg 70:1-4, 2004
70. Näslund E, Backman L, Holst JJ, Theodorsson E, Hellström PM: Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 8:253-260, 1998
71. Shak JR, Roper J, Perez-Perez GI, Tseng CH, Francois F, Gamagaris Z, Patterson C, Weinshel E, Fielding GA, Ren C, Blaser MJ: The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg 18:1089-1096, 2008
72. Ballantyne GH: Peptide YY (1-36) and peptide YY (3-36): Part I: distribution, release, and actions. Obes Surg 16:651-658, 2006
73. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR: Inhibition of food intake in obese subjects by peptide YY3-36N. N Engl J Med 349:941-948, 2003
74. Korner J, Leibel RL: To eat or not to eat: how the gut talks to the brain. N Engl J Med 349:926-928, 2003
75. Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL, Bessler M: Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity 14:1553-1561, 2006
76. Morínigo R, Moizé V, Musri M, Lacy AM, Navarro S, Marín JL, Delgado S, Casamitjana R, Vidal J: Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 91:1735-1740, 2006
77. Dezaki K, Sone H, Koizumi M, Nakata M, Kakei M, Nagai H, Hosoda H, Kangawa K, Yada T: Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance. Diabetes 55:3486-3493, 2006
78. Cummings DE, Foster-Schubert KE, Overduin J: Ghrelin and energy balance: focus on current controversies. Curr Drug Targets 6:153-169, 2005
79. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346:1623-1630, 2002
80. Geloneze B, Tambascia MA, Pilla VF, Geloneze SR, Repetto EM, Pareja JC: Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg 13:17-22, 2003
81. Faraj M, Havel PJ, Phélis S, Blank D, Sniderman AD, Cianflone K: Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88:1594-1602, 2003
82. Holdstock C, Engström BE, Ohrvall M, Lind L, Sundbom M, Karlsson FA: Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 88:3177-3183, 2003
83. Sundbom M, Holdstock C, Engström BE, Karlsson FA: Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg 17:304-310, 2007
84. Rubino F, Gagner M: Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 236:554-559, 2002
85. Rubino F, Marescaux J: Effect of duodenaljejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239:1-11, 2004
86. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J: The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244:741-749, 2006
87. Ramos AC, Galvão Neto MP, de Souza YM, Galvão M, Murakami AH, Silva AC, Canseco EG, Santamaría R, Zambrano TA: Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 kg/m 2 (LBMI). Obes Surg 19:307-312, 2009
88. Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M: First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis 4:55-59, 2008
89. Koopmans HS, Ferri GL, Sarson DL, Polak JM, Bloom SR: The effects of ileal transposition and ileal bypass on food intake and GI hormone levels in rats. Physiol Behav 33:601-609, 1984
90. Ohtani N, Sasaki I, Naito H, Shibata C, Tsuchiya T, Matsuno S: Effect of ileojejunal transposition of gastrointestinal motility, gastric emptying, and small intestinal transit in dogs. J Gastrointest Surg 3:516-523, 1999
91. Sarson DL, Scopinaro N, Bloom SR: Gut hormone changes after jejunoileal (JIB) or biliopancreatic (BPB) bypass surgery for morbid obesity. Int J Obes 5:471-480, 1981
92. Strader AD, Vahl TP, Jandacek RJ, Woods SC, D'Alessio DA, Seeley RJ: Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288:E447-E453, 2005
93. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP: The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43:587-592, 1994
94. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G: Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 55:2025-2031, 2006
95. Mari A, Manco M, Guidone C, Nanni G, Castagneto M, Mingrone G, Ferrannini E: Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 49:2136-2143, 2006
96. Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, Ferrannini E: Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 118:51-57, 2005
97. Camastra S, Gastaldelli A, Mari A, Bonuccelli S, Scartabelli G, Frascerra S, Baldi S, Nannipieri M, Rebelos E, Anselmino M, Muscelli E, Ferrannini E: Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 54:2093-2102, 2011
98. Campos GM, Rabl C, Peeva S, Ciovica R, Rao M, Schwarz JM, Havel P, Schambelan M, Mulligan K: Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg 14:15-23, 2010
99. Lima MM, Pareja JC, Alegre SM, Geloneze SR, Kahn SE, Astiarraga BD, Chaim EA, Geloneze B: Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic hyperinsulinemic clamp. J Clin Endocrinol Metab 95:3871-3875, 2010
100. Kashyap SR, Daud S, Kelly KR, Gastaldelli A, Win H, Brethauer S, Kirwan JP, Schauer PR: Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes 34:462-471, 2010
101. 2. Surg Endosc 23:1569-1573, 2009
102. Cohen R, Pinheiro JS, Correa JL, Schiavon CA: Laparoscopic Roux-en-Y gastric bypass for BMI < 35 kg/m 2: a tailored approach. Surg Obes Relat Dis 2:401-404, 2006
103. Yermilov I, McGory ML, Shekelle PW, Ko CY, Maggard MA: Appropriateness criteria for bariatric surgery: beyond the NIH guidelines. Obesity 17:1521-1527, 2009
104. Sarwer DB, Ritter S, Wadden TA, Spitzer JC, Vetter ML, Moore RH: Physicians' attitudes about referring their type 2 diabetes patients for bariatric surgery. Surg Obes Relat Dis. Electronically Published ahead of print on 30 January 2012 (doi: 10.1016/j.soard.2011.12.013)
105. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357:741-752, 2007
106. DiGiorgi M, Rosen DJ, Choi JJ, Milone L, Schrope B, Olivero-Rivera L, Restuccia N, Yuen S, Fisk M, Inabnet WB, Bessler M: Re-emergence of diabetes after gastric by-pass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 6:249-253, 2010
107. Chikunguwo SM, Wolfe LG, Dodson P, Meador JG, Baugh N, Clore JN, Kellum JM, Maher JW: Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric by-pass. Surg Obes Relat Dis 6:254-259, 2010
108. Laferrère B: Do we really know why diabetes remits after gastric bypass surgery? Endocrine 40:162-167, 2011